Nanogen Pharmaceutical Biotechnology JSC is a pioneering biopharmaceutical manufacturer headquartered in Ho Chi Minh City, Vietnam. Established in 1997, the company has grown into a leading research and innovation-driven enterprise with a workforce of 501 to 1,000 employees. Nanogen operates four advanced manufacturing plants and a dedicated R&D center, maintaining high-quality standards with WHO-GMP and TGA-GMP (Australia) certifications. The company specializes in the development and production of Active Pharmaceutical Ingredients (API), biosimilars, and finished dosage forms, including lyophilized powders, vials, and prefilled syringes.
Their extensive product portfolio focuses on critical therapeutic areas such as Hepatitis B and C treatments, cancer therapeutics, and anemia management. Notable products include PEGNANO, the first biosimilar of its kind in Asia, as well as FACEPTOR and MIRACEL for various oncology applications. Beyond its proprietary product lines, Nanogen provides comprehensive Contract Manufacturing Organization (CMO) and OEM services, leveraging state-of-the-art bioreactor purification systems. The company has a significant international footprint, exporting biological therapies and vaccines to over 15 countries across Asia, Europe, Africa, and the Americas. Nanogen is also recognized for its advanced innovation in vaccine development, notably progressing the NANO COVAX Covid-19 vaccine through Phase 3 clinical trials.